Find a Clinical Trial

(Diagnostic Trial) – Evaluating whether combining PET/imaging and MRI improves the detection of Prostate Cancer compared to Standard of Care.

Inclusion Criteria: Male participants aged 18 years or older with clinical suspicion of prostate cancer and no prior prostate biopsy.

More details coming soon.

This research study is available at the following locations: Urology Austin, Conrad Pearson, Southern Urology and Urology Associates

Comparing two surgical approaches for treating localized Prostate Cancer – Aquablation vs. Radical Prostatectomy

Inclusion Criteria: Male participants aged 45 years or older with a positive prostate biopsy with Grade Group 1–3, a PSA level of 20 or lower, and a prostate volume of 25 ml or greater.

This research study is available at the following locations: Urology Austin

Patient Information

More Information

Device study for the Treatment of Post Prostatectomy Stress Urinary Incontinence in Males

Inclusion Criteria: Male participants aged 45 years or older who have been diagnosed with prostate cancer and scheduled for robotic assisted radical prostatectomy.

This research study is available at the following locations: Urology Austin and Conrad Pearson

Learn More

A study to evaluate the impact of metastasis free survival with the addition of an investigational treatment for prostate cancer vs standard radiotherapy/ADPI treatment

Inclusion Criteria: Male participants aged 18 years or older with newly diagnosed high-risk prostate cancer and a confirmed BCRA1 or BCRA2 mutation.

More details coming soon.

This research study is available at the following locations: Urology Austin

Evaluating the safety and effectiveness of the combination study treatment lutetium +marketed treatments vs. Lutetium alone

Inclusion Criteria: Participants with newly diagnosed metastatic castrate resistant prostate cancer who are currently on second-generation ARPI medications and have a positive PET PSMA scan.

More details coming soon.

This research study is available at the following locations: Urology Austin

Comparing BMS vs. Investigators choice in therapy comprising either Docetaxel or Second-Generation Androgen Receptor

Inclusion Criteria: Participants with newly diagnosed metastatic castrate resistant prostate cancer who are undergoing androgen deprivation therapy with testosterone and have previous treatment with APRI’s

This research study is available at the following locations: Urology Austin

Evaluating the effectiveness of experimental drug (Lutetium + Standard of Care) vs. (Standard of Care Alone)

Inclusion Criteria: Participants who have previous treatment with APRI’s and have documented metastatic progression.

More details coming soon.

This research study is available at the following locations: Conrad Pearson, Southern Urology and Urology Associates

Evaluating the safety and Efficacy of the FloStent device in men suffering from Benign Prostatic Hyperplasia

Inclusion Criteria: Male participants aged 45 years or older with benign prostatic hyperplasia (BPH).

This research study is available at the following locations: Urology Austin, Conrad Pearson, Southern Urology, and Urology Associates

Learn More

Study to compare the Nitinol (iTind) device vs. UroLift device for patients with Benign Prostatic Hyperplasia

Inclusion Criteria: Male participants aged 50 years or older with benign prostatic hyperplasia (BPH).

This research study is available at the following locations: Conrad Pearson

Patient Brochure

Transurethral focused Ultrasound for the ablation of prostate tissue

Inclusion Criteria: Male participants with benign prostatic hyperplasia (BPH).

More details coming soon.

This research study is available at the following locations: Urology Austin, Conrad Pearson, Urology Associates

Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer

Inclusion Criteria: Participants aged 18 years or older with intermediate risk non muscle invasive bladder cancer.

This research study is available at the following locations: Urology Austin, Southern Urology, and Urology Associates

Recruitment Information

Comparing TAR-210 to intravesc chemo in patients with bladder cancer

Inclusion Criteria: Participants aged 18 years or older with a confirmed diagnosis of papillary non-muscle invasive bladder cancer.

This research study is available at the following locations: Urology Austin and Conrad Pearson

Recruitment Information

Study of V940 in Combination with BCG Versus BCG Monotherapy and or V940 by itself in Participants with High-risk

Inclusion Criteria: Participants aged 18 years or older with a confirmed diagnosis of high-risk non-muscle invasive bladder cancer.

This research study is available at the following locations: Urology Austin, Conrad Pearson, Southern Urology, and Urology Associates

Patient Information

Evaluating the Safety and Anti-Tumor Activity of Intravesical Instillation of TARA-002 in Adults with High-Grade Non-Muscle Invasive Bladder Cancer

Inclusion Criteria: Participants aged 18 years or older with a confirmed diagnosis of high-grade non-muscle invasive bladder cancer.

This research study is available at the following locations: Urology Austin, Conrad Pearson, and Urology Associates

Recruitment Information

Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC).

Inclusion Criteria: Participants aged 18 years or older with high-risk, high-grade non-muscle invasive bladder cancer (NMIBC) who are BCG naive, exposed and or unresponsive.

This research study is available at the following locations: Urology Austin

Study to evaluate either BCG +/- Anktiva in Patients with Bladder Cancer that have not received BCG

Inclusion Criteria: Participants aged 18 years or older with histologic confirmation of non-muscle invasive bladder cancer who are BCG naive.

This research study is available at the following locations: Urology Austin

Patient Information

Evaluating the safety and tolerability of EG-70 in participants with non-muscle invasive bladder cancer

Inclusion Criteria: Participants aged 18 years or older with BCG unresponsive non-muscle invasive bladder cancer with CIS, with or without coexisting papillary Ta/T1 tumors.

This research study is available at the following locations: Urology Austin

Patient Information